Effects and safety of rituximab in systemic sclerosis: An analysis from the European Scleroderma Trial and Research (EUSTAR) group

Suzana Jordan, Jörg H.W. Distler, Britta Maurer, Dörte Huscher, Jacob M. Van Laar, Yannick Allanore, Oliver Distler*, Tore K. Kvien, Paolo Airo, Juan José Alegre Sancho, Lidia Ananjeva, Codrina Michaela Ancuta, Martin Aringer, Alexandra Balbir-Gurman, Francesco Paolo Cantatore, Paola Caramaschi, Emmanuel Chatelus, Veronica Codullo, Dominique Farge-Bancel, Rosario FotiArmando Gabrielli, Jörg Henes, Ilka Herrgott, Florenzo Iannone, Francesca Ingegnoli, Esthela Loyo, Marco Matucci-Cerinić, Walid Ahmed Abdel Atty Mohamed, Ulf Müller-Ladner, Øyvind Palm, Sergiu Popa, Gabriela Riemekasten, Simona Rednic, Edoardo Rosato, Marta Saracco, Agneta Scheja, Vanessa Smith, Carina Mihai, Gabriela Szucs, Matija Tomšić, Gabriele Valentini, Ulrich A. Walker, Rene Westhovens, Sule Kurhan Yavuz, Thierry Zenone

*Korrespondierende/r Autor/-in für diese Arbeit
241 Zitate (Scopus)

Fingerprint

Untersuchen Sie die Forschungsthemen von „Effects and safety of rituximab in systemic sclerosis: An analysis from the European Scleroderma Trial and Research (EUSTAR) group“. Zusammen bilden sie einen einzigartigen Fingerprint.

Medizin & Biologie